1. Click here to sign the "Publish the NICE ME/CFS Guideline Now" petition.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 13th September 2021 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Fibromyalgianess and glucocorticoid persistence among patients with rheumatoid arthritis, 2021, Wallace et al

Discussion in 'Health News and Research unrelated to ME/CFS' started by Andy, Jul 23, 2021.

  1. Andy

    Andy Committee Member (& Outreach when energy allows)

    Messages:
    14,057
    Location:
    Hampshire, UK
    Abstract

    Objectives
    Over 1/3 of patients with rheumatoid arthritis (RA) exhibit evidence of fibromyalgianess, which is associated with higher rates of disability and inadequate responsiveness to RA treatment. Patients with RA often remain on glucocorticoids long-term, despite the known risk of dose-dependent morbidity. We undertook this study to examine the relationship between fibromyalgianess and glucocorticoid persistence among RA patients.

    Methods
    We followed participants with active RA on oral prednisone for ∼3 months after initiating a new disease-modifying anti-rheumatic drug (DMARD). Fibromyalgianess was measured using the Fibromyalgia Survey Questionnaire (FSQ), previously shown to correlate with key fibromyalgia features often superimposed upon RA. Severity of fibromyalgianess was stratified as follows: FSQ < 8 low, FSQ 8–10 moderate, and FSQ >10 high/very high. The association between baseline fibromyalgianess and glucocorticoid persistence, defined as prednisone use at three-month follow-up visit after DMARD initiation, was assessed using multiple logistic regression adjusted for baseline demographics, RA duration, serostatus, and inflammatory activity assessed using swollen joint count and C-reactive protein.

    Results
    Of the 97 participants on prednisone at baseline, 65% were still taking prednisone at follow-up. 57% of participants with low baseline fibromyalgianess had persistent glucocorticoid use, compared with 84% of participants with high or very high fibromyalgianess. After adjustment for non-inflammatory factors and inflammatory activity, participants with high/very high baseline fibromyalgianess were more likely to be taking prednisone at follow-up relative to those with low fibromyalgianess (Odds Ratio 4.99 [95% Confidence Interval 1.20–20.73]).

    Conclusion
    High fibromyalgianess is associated with persistent glucocorticoid use, independent of inflammatory activity.

    Paywall, https://academic.oup.com/rheumatolo...ract/doi/10.1093/rheumatology/keab583/6325524
     
    Peter Trewhitt likes this.
  2. chrisb

    chrisb Senior Member (Voting Rights)

    Messages:
    3,871

Share This Page